Investor Relations Home  
  News and Events  
  Fact Sheet
  Corporate Governance  
  Stock  Information 
  SEC Filings  
  Covering Analysts  
  Calendar of Events  
  Investor FAQ  
  Information Request  
  Contact IR  
HOME   

    STOCK QUOTE
MDCO - (NASDAQ)
$21.99   + 1.85
07-23-2008 at 4:15 PM ET

 


    INVESTOR TOOLS

 




Quotes delayed at least 20 minutes. Information provided by TurboFeed.

The Medicines Company is focused on advancing the treatment of critical care patients through to delivery of innovative, cost-effective medicines to the worldwide hospital marketplace.

Investors & Media

Investor Relations Home

The Medicines Company (Nasdaq: MDCO) specializes in acute care hospital pharmaceutical products. MDCO acquires, develops and commercializes products in late stages of their development. Its first acute care hospital product, Angiomax® (bivalirudin), is a direct thrombin inhibitor used as an anticoagulant in patients undergoing coronary angioplasty. MDCO is currently developing two additional late development stage pharmaceutical products as potential acute care hospital products.

more »

The Medicines Company Stock Chart
3 Mo.   6 Mo.   1 Yr.

Recent Releases

07-23-2008
The Medicines Company Reports Second Quarter and First Half 2008 Financial Results and Raises Full Year Top Line Guidance

07-14-2008
New Publication Shows Cleviprex(TM) is Effective for Rapid Treatment of Acute Hypertension After Cardiac Surgery

more »

Events

07-23-2008
2Q 2008 Earnings Call

04-23-2008
1Q 2008 Earnings Call

more »